Serhat Gumrukcu

Serhat Gumrukcu

MD PhD

Seraph Research Institute
Director

Seraph Medical and Surgery Center Director,Translational Research Dept

Dr. Gumrukcu’s research focuses on cancer immunotherapy, stem cell and transplant biology, and regenerative medicine. His main objective has been developing better stem cell transplant, and cell and gene therapy treatments for patients with cancer, rare genetic disorders, and infectious diseases.

His higher education and interest in other fields of science has led him to develop a different understanding of scientific research and discovery, where he approaches diseases and problems from different perspectives compared to his peers. He believes in developing an “upstream approach” where the therapeutic interventions like a gene delivery should happen at a biological stage that is much earlier than generation of the intended result. His research has shown, in treatments where a disease-specific immune response is aimed, an upstream approach results in a rather innate-like immunity which resembles the natural response of the immune system.

Dr. Gumrukcu is a member of American Society of Clinical Oncology (ASCO), International AIDS Society (IAS), HIV Medicine Association (HIVMA), and American Society of Gene & Cell Therapy (ASGCT) where he serves at Cancer Cell & Gene Therapy Committee and Infectious Diseases and Vaccines Committee.

Expertise and Research Interests

The Gumrukcu Lab studies gene and cell therapy particularly in the context of cancer (hematological and solid tumors), developing novel stem cell transplant methods for rare diseases, and innate molecular and cellular immunology in cancer and chronic infections like HIV/AIDS and HBV. The main objective is to develop better stem cell transplant and cell and gene therapy treatments for patients with cancer, rare genetic disorders, and infectious diseases.

In his past research, Dr Gumrukcu has developed a gene-modified autologous bone marrow transplant method that has a potential to facilitate increased engraftment in a non-myeloablative model. He has demonstrated the successful homing, engraftment and increased reconstitution capabilities of the modified bone marrow cells. Gumrukcu Lab now focuses on creating disease-specific gene therapy vectors to harness the potential of this method, which has a promising clinical use potential as an outpatient procedure in treating tens of different genetic disorders, as well as many cancers and HIV.

The current research in his laboratory focuses on studies to:

  • Genetic and intracellular mechanisms that contribute to the resistance or long-term control of HIV
  • Understand basic hematopoietic stem/progenitor cell (HSPC) biology and its changes in the event of gene modification
  • Clonal characteristics and clinical safety profile of gene-modified HSPCs
  • Mechanisms that contribute to graft-versus-tumor, graft-versus-leukemia or graft-versus-virus effects in allogeneic cell stem cell transplant and adoptive cell therapy models
  • Develop novel gene therapy methods and clinical protocols for cancer, HIV, and rare genetic diseases, especially enzyme deficiency disorders
  • Investigate safer, less toxic autologous HSPC transplant methods for patients with nonmalignant diseases
  • Develop novel gene and cell therapy protocols to induce rapid disease-specific humoral and cellular immune response in chronic infectious diseases
  • Study viral replication machinery to develop gene therapies that develop novel molecular host defense mechanisms